Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells

Patent metadata

Field	Value
Publication number	US-2016015682-A2
Application number	US-201414358861-A
Country	US
Kind code	A2
Filing date	Nov 20, 2012
Priority date	Nov 21, 2011
Publication date	Jan 21, 2016
Grant date	—

Abstract

The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.

First claim

1 . A method for treating diabetes or pre-diabetes comprising administering to a patient requiring protection of pancreatic islet cells a therapeutically effective amount of phytocannabinoid tetrahydrocannabivarin (THCV).

2 . The method as claimed in claim 1 , wherein the pancreatic islet cells to be protected are beta cells.

3 . The method as claimed in claim 1 wherein the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.

4 . The method as claimed in claim 1 , wherein the patient has or is pre-disposed to type 1 diabetes.

5 . The method as claimed in claim 1 , wherein the patient has or is pre-disposed to type 2 diabetes.

6 . The method as claimed in claim 5 , wherein the patient has or is pre-disposed to gestational diabetes.

7 . The method as claimed in claim 5 , which is a disease modifying treatment as opposed to a symptomatic treatment.

8 . The method as claimed in claim 7 , wherein the symptomatic treatment is obesity.

9 . The method as claimed in claim 1 , wherein the THCV is administered in combination with one or more additional anti-diabetic medicine and or anti-obesity medicines.

10 . The method as claimed in claim 9 , wherein the additional anti-diabetic medicine is metformin.

11 . The method as claimed in claim 9 , wherein the additional anti-diabetic medicine is from the sulphonylurea class of anti-diabetic drugs.

12 . The method as claimed in claim 1 , wherein the THCV is a synthetic cannabinoid or an isolated phytocannabinoid.

Assignees

• Cawthorne Michael
• Stott Colin
• Wright Stephen
• Gw Pharma Ltd

Inventors

• Cawthorne Michael
• Stott Colin
• Wright Stephen

Classifications

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/155

  Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K36/3482

  Cannabis · CPC title